ALK and lung cancer: Recent studies have demonstrated that lung cancers harboring ALK rearrangements do not respond to EGFR-specific tyrosine kinase inhibitors, but benefit from a small molecule inhibitor targeting the ALK kinase (ie, crizotinib [Xalkori®, Pfizer, Inc.]).